“In a prospective, multicenter study, the 31-GEP identified patients at increased risk of tumor recurrence and added significant prognostic value to AJCC staging”, J of Skin, vol. 8, no. 6, p. s504, Nov. 2024, doi: 10.25251/skin.8.supp.504.